Medpace Holdings logo
01P logo

Medpace HoldingsDB:01P Stock Report

Market Cap €9.6b
Share Price
n/a
1Y-15.5%
7D-3.5%
Portfolio Value
​
View

Medpace Holdings, Inc.

DB:01P Stock Report

Market Cap: €9.6b

01P Stock Overview

Provides clinical research-based drug and medical device development services in North America, Europe, and Asia. More details

01P fundamental analysis
Snowflake Score
Valuation4/6
Future Growth3/6
Past Performance6/6
Financial Health5/6
Dividends0/6

Rewards

Trading at 59.5% below our estimate of its fair value

Earnings are forecast to grow 9.56% per year

Earnings grew by 43.1% over the past year

Risk Analysis

No risks detected for 01P from our risk checks.

My Notes

Capture your thoughts, links and company narrative

Medpace Holdings, Inc. Competitors

Sartorius

XTRA:SRT3

€15.0b

Gerresheimer

XTRA:GXI

€2.8b

SCHOTT Pharma KGaA

XTRA:1SXP

€3.8b

Dermapharm Holding

XTRA:DMP

€2.1b

Price History & Performance

Summary of share price highs, lows and changes for Medpace Holdings
Historical stock prices
Current Share PriceUS$313.40
52 Week HighUS$418.70
52 Week LowUS$286.00
Beta1.36
1 Month Change-4.63%
3 Month Change-2.49%
1 Year Change-15.53%
3 Year Change128.76%
5 Year Change270.89%
Change since IPO1,110.79%

Recent News & Updates

Recent updates

Shareholder Returns

01PDE Life SciencesDE Market
7D-3.5%-2.4%0.9%
1Y-15.5%-9.7%14.4%

Return vs Industry: 01P underperformed the German Life Sciences industry which returned -9.1% over the past year.

Return vs Market: 01P underperformed the German Market which returned 15.1% over the past year.

Price Volatility

Is 01P's price volatile compared to industry and market?
01P volatility
01P Average Weekly Movement4.4%
Life Sciences Industry Average Movement6.3%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.6%
10% least volatile stocks in DE Market2.6%

Stable Share Price: 01P has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: 01P's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19925,900August Troendlewww.medpace.com

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

Medpace Holdings, Inc. Fundamentals Summary

How do Medpace Holdings's earnings and revenue compare to its market cap?
01P fundamental statistics
Market cap€9.58b
Earnings (TTM)€389.87m
Revenue (TTM)€2.03b

24.7x

P/E Ratio

4.7x

P/S Ratio

Is 01P overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
01P income statement (TTM)
RevenueUS$2.11b
Cost of RevenueUS$682.10m
Gross ProfitUS$1.43b
Other ExpensesUS$1.02b
EarningsUS$404.34m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)13.27
Gross Margin67.66%
Net Profit Margin19.17%
Debt/Equity Ratio0%

How did 01P perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/28 11:20
End of Day Share Price 2025/02/28 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Medpace Holdings, Inc. is covered by 19 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Eric ColdwellBaird
Ishan MajumdarBaptista Research
Erin Wilson WrightCredit Suisse